LiteVax part of the consortium for the development of a highly immunogenic HER2-vaccine against breast cancer.
The Eurostars project will support the development of a novel breast cancer HER2 vaccine including the LiteVax Adjuvant. We expect that LVA synergizes with HER2 antigen in the induction of high antibody titers against HER2. These high antibody titers are key for an effective therapeutic HER2 vaccin.
February 20 - 22: Litevax joins the vaccine innovation mission to Delhi, India
February 22 - 24: Litevax attends BioAsia in Hyderabad, India
February 18 - March 6: LiteVax visits private and public vaccine R&D organizations in Asia to discuss proprietary adjuvant technology and to establish collaboration.